Prognostic Value of Metabolic Response Measured by FDG-PET-CT in Patients with Breast Cancer Liver Metastasis Treated with Stereotactic Body Radiotherapy

Ozan Cem GÜLER,1 Neşe TORUN,2 Berna AKKUŞ YILDIRIM,1 Cem ÖNAL1

1Department of Radiation Oncology, Başkent University Faculty of Medicine, Adana-Turkey
2Department of Nuclear Medicine, Başkent University Faculty of Medicine, Adana-Turkey

OBJECTIVE
To investigate the impact of metabolic response measured by 18-fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET-CT) in patients with breast cancer liver metastasis (BCLM) treated with stereotactic body radiotherapy (SBRT).

METHODS
The medical records of 17 patients with BCLM treated with SBRT between March 2013 and October 2017 were investigated retrospectively. Patients received SBRT for their liver metastasis, and thereafter, a second FDG-PET-CT was performed for response assessment in a median of 4.1 (2.2–8.2) months. A total of 54 Gy in three fractions were delivered to liver metastatic lesions. The standardized uptake value (SUV) and survival rates were evaluated.

RESULTS
After a median follow-up time of 11.5 (3.2–48.9) months, there was a significant difference between pre- and post-SBRT SUVs (p<0.001). Complete metabolic response was observed in 14 (82%) patients, partial metabolic response was observed in 2 (12%) patients, and stable metabolic disease/progressive metabolic disease was observed in 1 (6%) patient at post-treatment PET-CT. The 1- and 2-year overall survival rates were 68% and 57%, respectively, and the 1- and 2-year progression-free survival rates were 38% and 25%, respectively.

CONCLUSION
PET-CT is an effective tool for response monitoring in patients with BCLM treated with SBRT.

Keywords: Breast cancer; liver metastasis; positron emission tomography; stereotactic body radiotherapy.

Introduction
The liver is one of the most common metastatic sites for many cancer types, and liver metastasis (LM) is a substantial cause of morbidity and mortality.[1] Local treatment options for LM are surgery, transarterial chemoembolization (TACE), radiofrequency ablation (RFA), and radiotherapy (RT). These local treatments could be applied alone or as an adjunct to systemic chemotherapeutic agents in order to improve outcomes.[2,3]

Patients with breast cancer with metastasis had dismal 5-year survival rates of approximately 25%.[4] Of those, patients with liver or brain metastasis have worse
were investigated retrospectively. Patients had LM either at diagnosis or as a disease progression after curative treatment. Only in patients with ≤5 metastasis or primary tumor remained under control, SBRT to LM was performed. Patient selection criteria included maximum LM diameter <6 cm, Karnofsky Performance Status ≥70, normal coagulation function tests, Child–Pugh Status A–B, and life expectancy >3 months. The FDG-PET-CT was performed in all of the patients before liver SBRT and a median of 4.1 (2.2–8.2) months after completion of liver SBRT. Treatment response was performed according to “PET Response Criteria in Solid Tumors” (PERCIST) for all patients [16] (Fig. 1). Complete metabolic response (CMR) was accepted if all FDG-avid lesions disappeared. Significant reduction in the standardized uptake values (SUVs) was accepted as partial metabolic response (PMR). Stable (SMD) or progressive metabolic disease (PMD) was accepted if there was no visible change or unequivocal progression of the primary tumor.

FDG-PET-CT

Patients were imaged using a dedicated PET/CT system (Discovery-STE 8; General Electric Medical System, Milwaukee, WI, USA) as previously described. Briefly, patients fasted for at least 6 h before intravenous administration of 370 to 555 MBq (10Y15 mCi) FDG. Pre-injection blood glucose levels were measured to ensure that they were <150 mg/dL. During the distribution phase, patients were in supine position in a quiet room. Combined image acquisition started 60 min after FDG injection. Patients were scanned on a flat-panel carbon fiber composite table insert. First, an unenhanced CT scan (5-mm slice thickness) from the base of the skull to the inferior border of the pelvis was
obtained using a standardized protocol (140 kV and 80 mA). The subsequent PET scan was acquired in a three-dimensional mode from the base of the skull to the inferior border of the pelvis (6–7 bed positions, 3 min per bed position) without repositioning the patient on the table. CT and PET images were obtained with the patient breathing shallowly. Attenuation was corrected using the CT images. Areas of FDG uptake were categorized as malignant based on location, intensity, shape, size, and visual correlation with CT images to differentiate physiological uptake from pathological uptake.

SBRT technique
Patients underwent 1.25 mm multislice contrast-enhanced planning CT from tracheal bifurcation to the lower border of the kidneys for simulation (Optima 580; GE Healthcare, Waukesha, WI, USA). Patients were positioned supine with arms above the head and immobilized using a BodyFIX® bluebag with vacuum wrap (Elekta, Stockholm, Sweden). In addition, an abdominal compress was used to minimize organ motions.

Magnetic resonance imaging and FDG-PET-CT were fused with planning CTs to help the clinicians to localize the target volume precisely, where appropriate. Gross tumor volume (GTV) included the visible tumor in imaging, but no clinical tumor volume was defined. Planning tumor volume (PTV) was expanded 7 mm in all directions except for 12 mm craniocaudal margin.[12,18] No fiducial markers were implanted before treatment planning.

A healthy liver was calculated as liver volume minus GTV. In addition to the liver, other organs at risk (OARs) under consideration were the spinal cord, kidneys, stomach, duodenum, heart, small bowel, esophagus, and ribs according to the location of the lesion. The prescribed dose was 54 Gy delivered in three fractions, and the dose was prescribed to 90% isodose line. Treatment was delivered every other day. PTV coverage was aimed at >95% of the prescribed dose (Fig. 2).

Plans were calculated by the Monaco Treatment Planning System (Elekta Ltd., Crawley, UK) using the Monte Carlo algorithm and a sliding window multileaf collimator delivery technique. All treatment plans were performed for delivery using an Axesse linear accelerator (Elekta AB, Stockholm, Sweden). Volumetric modulated arc therapy plans consisted of double or triple 360° arcs.

Previously published OAR dose constraints during liver SBRT were used.[12,19] At least 700 mL of healthy liver should receive <15 Gy in three fractions. Other dose constraints of OARs included total kidney volume <15 Gy (volume receiving 15 Gy should be <35%), maximum dose (D1cc) for spinal cord <18 Gy, D1cc for duodenum <21 Gy, D1cc for small bowel <21 Gy, D1cc for esophagus <21 Gy, D1cc for stomach <21 Gy, D1cc for heart <30 Gy, and D1cc for ribs <30 Gy.

Statistical analysis
Statistical analyses were performed using the SPSS 22.0 software (SPSS, Chicago, IL, USA). The LC, overall survival (OS), and progression-free survival (PFS) rates
had LM during the follow-up period. Eleven (65%) patients had only LM, whereas 6 (35%) patients had more than one metastatic site. LM was observed at a median of 28.3 (0–104.5) months.

After a median follow-up time of 11.5 (3.2–48.9) months, 9 (53%) patients had distant disease recurrence. Disease progression was observed at a median of 8 (0.8–32.8) months after completion of liver SBRT. At the last follow-up, 1 (6%) patient was alive with no evidence of disease, 9 (53%) patients were alive with disease, and 7 (41%) patients died due to disease progression. The 1- and 2-year OS rates were 68% and 57%, respectively, and the 1- and 2-year PFS rates were 38% and 25%, respectively (Fig. 3).

There were no grade 4 or 5 toxicities observed. However, mild to moderate dizziness was seen during the SBRT period and disappeared at the end of treatment. Furthermore, there was no radiation-induced liver disease observed.

**PET analysis**

The median pre-SBRT SUVmax of LM was 6.88 (range: 4.06–16.10), and the median post-SBRT SUVmax was 0 (range: 0–5.30). There was a significant difference between pre- and post-SBRT SUVs (p<0.001). CMR was observed in 14 (82%) patients, PMR was observed in 2 (12%) patients, and SMD/PMD was observed in 1 (6%) patient at post-treatment PET-CT.

### Table 1: Patient characteristics

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age (years)</th>
<th>Tumor stage</th>
<th>LM timing</th>
<th>Other metastatic sites</th>
<th>Primary treatment</th>
<th>Adjuvant treatment</th>
<th>OS (months)</th>
<th>PFS (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>27</td>
<td>TxNx</td>
<td>de novo</td>
<td>Lung</td>
<td>S, C, R</td>
<td>C</td>
<td>4.90</td>
<td>.83</td>
</tr>
<tr>
<td>2</td>
<td>31</td>
<td>T2N1</td>
<td>progression</td>
<td>Bone</td>
<td>S, C, R</td>
<td>C, H</td>
<td>15.43</td>
<td>9.10</td>
</tr>
<tr>
<td>3</td>
<td>32</td>
<td>T2N3</td>
<td>progression</td>
<td>Lung</td>
<td>S, C, R</td>
<td>Xeloda</td>
<td>48.87</td>
<td>12.63</td>
</tr>
<tr>
<td>4</td>
<td>34</td>
<td>T2N2</td>
<td>progression</td>
<td>Bone</td>
<td>S, C</td>
<td>C</td>
<td>8.97</td>
<td>8.97</td>
</tr>
<tr>
<td>5</td>
<td>36</td>
<td>T4N1</td>
<td>progression</td>
<td>Lung</td>
<td>S, C, R</td>
<td>C</td>
<td>6.87</td>
<td>6.87</td>
</tr>
<tr>
<td>6</td>
<td>37</td>
<td>T2N3</td>
<td>progression</td>
<td>Bone</td>
<td>S, C, R</td>
<td>C</td>
<td>11.87</td>
<td>1.67</td>
</tr>
<tr>
<td>7</td>
<td>38</td>
<td>TxN2</td>
<td>progression</td>
<td>Bone</td>
<td>S, C, R</td>
<td>C</td>
<td>7.47</td>
<td>7.47</td>
</tr>
<tr>
<td>8</td>
<td>40</td>
<td>T2N2</td>
<td>progression</td>
<td>Bone</td>
<td>S, C</td>
<td>C, H</td>
<td>32.77</td>
<td>32.77</td>
</tr>
<tr>
<td>9</td>
<td>44</td>
<td>T3N2</td>
<td>progression</td>
<td>Lung</td>
<td>S, C, R</td>
<td>H</td>
<td>25.87</td>
<td>9.70</td>
</tr>
<tr>
<td>10</td>
<td>49</td>
<td>T1N0 (bilat.)</td>
<td>progression</td>
<td>None</td>
<td>S, C, R</td>
<td>Vinorelbiv</td>
<td>8.93</td>
<td>6.20</td>
</tr>
<tr>
<td>11</td>
<td>52</td>
<td>T3N1</td>
<td>progression</td>
<td>Bone</td>
<td>S, C, R</td>
<td>C</td>
<td>11.17</td>
<td>10.63</td>
</tr>
<tr>
<td>12</td>
<td>52</td>
<td>T2N2</td>
<td>progression</td>
<td>None</td>
<td>S, C, R</td>
<td>C, H</td>
<td>25.83</td>
<td>3.90</td>
</tr>
<tr>
<td>13</td>
<td>52</td>
<td>T2N3</td>
<td>progression</td>
<td>Bone</td>
<td>S, C, R</td>
<td>C</td>
<td>5.83</td>
<td>5.83</td>
</tr>
<tr>
<td>14</td>
<td>55</td>
<td>T3N0</td>
<td>progression</td>
<td>None</td>
<td>S, C, R</td>
<td>-</td>
<td>12.83</td>
<td>12.83</td>
</tr>
<tr>
<td>15</td>
<td>63</td>
<td>TxN2</td>
<td>progression</td>
<td>Bone</td>
<td>S, C, R</td>
<td>C, H</td>
<td>3.20</td>
<td>3.20</td>
</tr>
<tr>
<td>16</td>
<td>65</td>
<td>TxN2</td>
<td>progression</td>
<td>Lung</td>
<td>S, C, R</td>
<td>Xeloda</td>
<td>11.53</td>
<td>11.53</td>
</tr>
<tr>
<td>17</td>
<td>67</td>
<td>TxN2</td>
<td>progression</td>
<td>Lung</td>
<td>S, C, R</td>
<td>H</td>
<td>28.70</td>
<td>8.03</td>
</tr>
</tbody>
</table>
Discussion

In the current study, we demonstrated that PET-CT is an effective tool for response monitoring in patients with BCLM treated with SBRT. The 1- and 2-year OS rates for patients with BCLM treated with liver SBRT and systemic chemotherapy were 68% and 57%, respectively, and the 1- and 2-year PFS rates were 38% and 25%, respectively. No grade 4 or 5 toxicities were observed. Although an excellent LC was achieved, 9 (53%) patients had distant disease progression in a median of 8 months after liver SBRT.

The most common metastatic sites for patients with breast cancer are the bones, lungs, liver, and brain. LM may be observed as the de novo or as the site of recurrence in approximately 15% of patients.[4] In a “Surveillance Epidemiology and End Results” database, Wu et al.[4] demonstrated that patients with BCLM have worse outcomes compared with lung or bone metastasis. Additionally, patients with recurrences isolated to limited number of organs (<5), so called as oligometastasis, are considered to have better prognosis.[21] Oligometastasis has been first described by Hellman et al. in 1995.[21] Aggressive local treatments to oligometastatic sites may potentially reduce the risk of metastatic disease by removing the metastasis source, thereby improving outcomes.[22,23] Surgery, RFA, TACE, and RT are local treatment options for patients with oligometastasis.[6,24–26] Although surgery remains the treatment of choice in patients with BCLM, it could be applied only for a selective cohort of patients due to morbidity and mortality risks. TACE is a less invasive local treatment compared with surgery, and its efficacy for LC has been confirmed.[27] The reported OS, median disease-free survival, and response rates after TACE were 7.3–47.0 months, 2.9–17 months, and 7%–74%, respectively. Pooled grade 3–4 side effects were reported up to 17%.[27] The efficacy of RFA had been shown in various trials in the management of LM.[28–30] The response rates after RFA were 63%–97%, and the 5-year survival rates ranged from 27% to 30%. Although RFA is a minimally invasive method as an alternative to surgery, the reported morbidity and mortality rates were 9%–10% and 0.3%–2.2%, respectively.[28–30]. In our study, no patients experienced grade 4 or 5 toxicities, and our data on toxicity are consistent with the literature.

SBRT offers an alternative, non-invasive, and conservative approach for LM treatment. Several prospective and retrospective studies demonstrated the feasibility of SBRT for LM.[3,8–12,25] In these studies, LMs were treated in 1–12 fractions to a total dose of 18–60 Gy. The 2-year LC rates ranged from 66% to 90%, and the 2-year OS rates were 32%–81%. Nevertheless, different patient selection, different histologies, and extra-hepatic metastasis could cause the changes in OS and LC. In our study, patients with BCLM received 54 Gy in three fractions in a homogeneous group of cohort and dose-fraction schedule. The 1- and 2-year OS and PFS rates were 68% and 57% and 38% and 25%, respectively.

The utility of PET-CT for assessing outcomes in patients with oligometastasis treated with SBRT was initially investigated by Solanki et al.[31] After a median follow-up of 14 months, they reported that PET
response to SBRT enables metabolic tumor response in tumors non-measurable by CT, and higher SBRT doses correlate with long-term PET response in 31 patients with 58 lesions. Fendler et al.[20] investigated 80 patients with LM from colorectal cancer treated with 90Y radio embolization. They found that patients with a change in metabolic tumor volume or total lesion glycolysis have significantly longer survival than those without changes in PET parameters (92 vs. 49 weeks, p=0.006 and 91 vs. 48 weeks, p=0.025, respectively). [20] The changes in SUVmax in PET-CT in LM were investigated by Stinauer et al.[32] They reported that the estimated SUVmax decay half-time is 2 months. In our study, there was a significant difference between pre-SBRT SUV of LM 6.88 (range: 4.06–16.10) and post-SBRT SUV 0 (range: 0–5.30) (p<0.001). CMR was observed in 14 (82%) patients, PMR was observed in 2 (12%) patients, and SMD/PMD was observed in 1 (6%) patient at post-treatment PET-CT.

Our study has several limitations while interpreting the results. First, the retrospective nature of the study is the main limitation that may cause an inherent bias. Second, a small sample size restrained us from defining the prognostic factors affecting OS and PFS. Third, the follow-up time is relatively short for accurate decisions. Finally, the systemic treatment varied both before and after liver SBRT and absolutely influenced the treatment outcomes. Nevertheless, the present study is important because we analyzed only BCLM, only one type of dose fractionation with the same SBRT technique in each patient.

**Conclusion**

To the best of our knowledge, this is the first study to evaluate the impact of metabolic response measured by FDG-PET-CT in patients with BCLM treated with SBRT. SBRT is a conservative approach with similar LC rates compared with other invasive/minimally invasive local treatments with better toxicity profile. PET-CT is an effective tool for evaluating treatment response in patients with oligometastasis. Prospective trials are warranted for future directions and accurate decisions.

**Ethical committee approval:** This study was conducted in accordance with local ethical rules.

**Peer-review:** Externally peer-reviewed.

**Conflict of Interest:** None declared.


**References**


